Entries by CAPTIS

Vertex to acquire US biotech firm Semma Therapeutics for £785m

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type The post Vertex to acquire US biotech firm Semma Therapeutics for £785m appeared first on Pharmaceutical Business review.

AstraZeneca’s anifrolumab meets primary endpoint in phase III SLE trial

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial.  Both arms received standard of care in the study. Anifrolumab is The post AstraZeneca’s anifrolumab meets primary endpoint in phase III SLE trial appeared first on Pharmaceutical Business review.